Related to Teva Eyes $2B+ Charges from Its Generic Protonix Launch

• Pfizer, Medivation Nix Development of Alzheimer Disease Therapy
  
• Merck to Pay Canadian Vioxx Claimants up to C$26.4M
  
• Watson Buys Ascent for $393M to Bolster Generics Business in Australia, Southeast Asia
  
• Pfizer’s Inlyta Approved in U.S. as Therapy for Advanced Renal Cell Carcinoma
  
• UPenn Cancer Institute's Suit Against Ex-Director Reflects Greater Focus on IP Protection
  
• BioSante, Teva Win FDA Nod for Male Hypogonadism Therapy
  
• India's Top Court Set to Hear Novartis Challenge to Patent Law
  
• Pfizer, Biocon End Insulin Biosimilars Partnership
  
• Watson Rumored to Be Talking to Actavis About a €5B Acquisition Deal
  
• Enterome Raises €5M to Develop Gut Bacteria-Based Disease and Drug-Response Biomarkers
  
• Goldman Sachs Points to Possible Three-Phase Breakup of Pfizer Businesses
  
• Shire’s Mesalamine MMX Fails Primary Endpoint in Phase III Diverticulitis Study
  
• Valeant to Purchase Certain Assets from Atlantis Pharma in Mexico
  
• Watson to Buy Actavis for $5.6B, Creating Generics Firm with $8B Pro Forma Revenues
  
• Protalix, Pfizer Report FDA Approval of Plant-Derived Gaucher Disease ERT Elelyso
  
• Novartis to Buy Dermatology Generics Firm Fougera for $1.525B Cash
  
• NIH’s NCATS Establishes $20M Collaborative Drug Repositioning Initiative
  
• Pfizer’s Torisel Misses Endpoints in Renal Cell Carcinoma Trial Testing Second-Line Setting
  
• FDA Clears Pfizer’s Lyrica for Spinal Cord Injury Neuropathic Pain
  
• BMS, Pfizer Fail to Win FDA Sanction for Stroke Prevention Drug